SAN

93.05

-0.42%↓

MRK1

115.25

+0.26%↑

SHL.DE

48.27

-0.06%↓

ARGX

513.4

-0.12%↓

FRE

43.3

-0.57%↓

SAN

93.05

-0.42%↓

MRK1

115.25

+0.26%↑

SHL.DE

48.27

-0.06%↓

ARGX

513.4

-0.12%↓

FRE

43.3

-0.57%↓

SAN

93.05

-0.42%↓

MRK1

115.25

+0.26%↑

SHL.DE

48.27

-0.06%↓

ARGX

513.4

-0.12%↓

FRE

43.3

-0.57%↓

SAN

93.05

-0.42%↓

MRK1

115.25

+0.26%↑

SHL.DE

48.27

-0.06%↓

ARGX

513.4

-0.12%↓

FRE

43.3

-0.57%↓

SAN

93.05

-0.42%↓

MRK1

115.25

+0.26%↑

SHL.DE

48.27

-0.06%↓

ARGX

513.4

-0.12%↓

FRE

43.3

-0.57%↓

Search

Laboratorios Farmaceuticos Rovi SA

Abrir

SetorSaúde

51.8 -0.58

Visão Geral

Variação de preço das ações

24h

Atual

Mín

51.5

Máximo

52.25

Indicadores-chave

By Trading Economics

Rendimento

-57M

32M

Vendas

199M

434M

P/E

Médio do Setor

19.029

54.533

EPS

0.354

Rendimento de Dividendos

1.8

Margem de lucro

7.411

Funcionários

2,197

EBITDA

40M

138M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+47.25% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.80%

2.41%

Próximos Ganhos

30 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-707M

2.7B

Abertura anterior

52.38

Fecho anterior

51.8

Sentimento de Notícias

By Acuity

50%

50%

174 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de mai. de 2025, 23:48 UTC

Ações em Alta

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 de mai. de 2025, 23:07 UTC

Principais Notícias

Fortescue Energy CEO to Resign in Executive Overhaul

22 de mai. de 2025, 23:03 UTC

Grandes Movimentos do Mercado

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 de mai. de 2025, 23:59 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 de mai. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 de mai. de 2025, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de mai. de 2025, 23:23 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

22 de mai. de 2025, 23:23 UTC

Conversa de Mercado

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 de mai. de 2025, 23:12 UTC

Principais Notícias

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22 de mai. de 2025, 21:54 UTC

Principais Notícias

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2025, 20:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 de mai. de 2025, 20:39 UTC

Ganhos

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 de mai. de 2025, 20:36 UTC

Principais Notícias

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 de mai. de 2025, 20:36 UTC

Principais Notícias
Ganhos

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 de mai. de 2025, 20:32 UTC

Principais Notícias
Ganhos

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 de mai. de 2025, 20:27 UTC

Principais Notícias

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 de mai. de 2025, 20:20 UTC

Principais Notícias

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 de mai. de 2025, 20:17 UTC

Principais Notícias

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 de mai. de 2025, 20:16 UTC

Ganhos

Intchains Group 1Q Rev $18.2M >ICG

22 de mai. de 2025, 20:15 UTC

Principais Notícias

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 de mai. de 2025, 20:08 UTC

Principais Notícias
Ganhos

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 de mai. de 2025, 20:05 UTC

Principais Notícias

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 de mai. de 2025, 20:04 UTC

Ganhos

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 de mai. de 2025, 20:04 UTC

Ganhos

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 de mai. de 2025, 20:01 UTC

Ganhos

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 de mai. de 2025, 20:01 UTC

Ganhos

Workday 1Q Net $68M >WDAY

22 de mai. de 2025, 20:01 UTC

Ganhos

Workday 1Q EPS 25c >WDAY

22 de mai. de 2025, 20:01 UTC

Ganhos

Workday 1Q Adj EPS $2.23 >WDAY

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

47.25% parte superior

Previsão para 12 meses

Média 77.75 EUR  47.25%

Máximo 90 EUR

Mínimo 65.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

174 / 382 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.